These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15828224)

  • 21. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [PPARs and cell-cell or cell-extracellular matrix interactions].
    Murad H; Fiatte C; Brunner E; Huin-Schohn C; Schohn H; Bécuwe P; Domenjoud L; Dauça M
    Med Sci (Paris); 2007 May; 23(5):515-8. PubMed ID: 17502068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
    Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
    J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P; Fruchart JC; Staels B
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
    Sertznig P; Seifert M; Tilgen W; Reichrath J
    J Cell Physiol; 2007 Jul; 212(1):1-12. PubMed ID: 17443682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.
    Rubin GL; Zhao Y; Kalus AM; Simpson ER
    Cancer Res; 2000 Mar; 60(6):1604-8. PubMed ID: 10749129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptors: new players in the field of reproduction.
    Toth B; Hornung D; Scholz C; Djalali S; Friese K; Jeschke U
    Am J Reprod Immunol; 2007 Sep; 58(3):289-310. PubMed ID: 17681045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hyperlipidemia and peroxisome proliferator-activated receptor (PPAR)--regulation of the PPARalpha gene by CLOCK: BMAL1].
    Inoue I
    Nihon Rinsho; 2005 Apr; 63(4):643-56. PubMed ID: 15828232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activators of the nuclear receptor PPARgamma enhance colon polyp formation.
    Saez E; Tontonoz P; Nelson MC; Alvarez JG; Ming UT; Baird SM; Thomazy VA; Evans RM
    Nat Med; 1998 Sep; 4(9):1058-61. PubMed ID: 9734400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PPARs-mediated intracellular signal transduction].
    Fujii H
    Nihon Rinsho; 2005 Apr; 63(4):565-71. PubMed ID: 15828221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The structures and functions of peroxisome proliferator-activated receptors (PPARs)].
    Takahashi N; Goto T; Kusudo T; Moriyama T; Kawada T
    Nihon Rinsho; 2005 Apr; 63(4):557-64. PubMed ID: 15828220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.
    Han C; Demetris AJ; Michalopoulos GK; Zhan Q; Shelhamer JH; Wu T
    Hepatology; 2003 Jul; 38(1):167-77. PubMed ID: 12829999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer.
    Han SW; Roman J
    World J Biol Chem; 2010 Mar; 1(3):31-40. PubMed ID: 21537367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PPARs in atherosclerosis].
    Toyoshima H; Yamada N
    Nihon Rinsho; 2005 Apr; 63(4):657-8. PubMed ID: 15828233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PPARgamma and Apoptosis in Cancer.
    Elrod HA; Sun SY
    PPAR Res; 2008; 2008():704165. PubMed ID: 18615184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Physiological functions of PPARs].
    Takada I; Kato S
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():251-5. PubMed ID: 23513846
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibition of the Low Density Lipoprotein-Induced Vascular Smooth Muscle Cell Growth by PPARgamma Ligands.
    Gouni-Berthold I; Sachinidis A
    Drug News Perspect; 2002 Jan; 15(1):5-9. PubMed ID: 12677238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mechanism for the action of PPARs].
    Yamashita D; Shimizu M; Osumi T
    Nihon Rinsho; 2005 Apr; 63(4):536-7. PubMed ID: 15828217
    [No Abstract]   [Full Text] [Related]  

  • 39. PPARs and lipid ligands in inflammation and metabolism.
    Harmon GS; Lam MT; Glass CK
    Chem Rev; 2011 Oct; 111(10):6321-40. PubMed ID: 21988241
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of TLRs and nuclear PPARγ receptors on the mechanisms of intestinal carcinogenesis.
    Orzechowska-Jastrząb A; Ptak-Belowska A; Targosz A
    Folia Med Cracov; 2019; 59(2):23-33. PubMed ID: 31659346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.